Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human Cathepsin E Antibody, R&D Systems™

Goat Polyclonal Antibody has been used in 4 publications
Supplier: R&D Systems AF1294SP
This item is not returnable.
View return policy
Description
Cathepsin E Polyclonal specifically detects Cathepsin E in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunoprecipitation.Specifications
Cathepsin E | |
Polyclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
CATE, cathepsin E, CTSE, EC 3.4.23, EC 3.4.23.34, erythrocyte membrane aspartic proteinase, slow-moving proteinase | |
Goat | |
Affinity Purified | |
RUO | |
1510 | |
Reconstitute at 0.2 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. |
Western Blot, Immunohistochemistry, Immunoprecipitation | |
LYOPH | |
Western Blot 0.1 ug/mL, Immunohistochemistry 5-15 ug/mL, Immunoprecipitation 25 ug/mL | |
NP_001901 | |
CTSE | |
Mouse myeloma cell line NS0-derived recombinant human Cathepsin E Ile54-Pro396 Accession # NP_001901 | |
25 μg | |
Primary | |
Detects human pro and active Cathepsin E in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 40% cross-reactivity with recombinant mouse Cathepsin E is observed and less than 2% cross-reactivity with recombinant human (rh) Cathepsin D and rhBACE is observed. | |
Human | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction